UBS raised the firm’s price target on Teva to $26 from $24 and keeps a Buy rating on the shares. UBS views duvakitug Phase 2 data in Q4 as an attractive catalyst for Teva’s stock, with significant upside and limited downside potential, the analyst tells investors in a research note. Beyond duvakitug, the firm sees scope for stock upside from a FY24 beat and raise and potential API sale.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue